WuXi XDC Cayman (HKSE:02268) Net Income From Continuing Operations : HK$1,146 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. WuXi XDC Cayman's net income from continuing operations for the six months ended in Dec. 2024 was HK$621 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was HK$1,146 Mil.

WuXi XDC Cayman Net Income From Continuing Operations Historical Data

The historical data trend for WuXi XDC Cayman's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Net Income From Continuing Operations Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

38.37

81.86

218.65

393.34

1,302.34

WuXi XDC Cayman Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial			85.33	193.83	116.30	525.60	620.74

WuXi XDC Cayman Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,146 Mil.

WuXi XDC Cayman Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

L74:Germany

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu Province, Wuxi, CHN

Website

https://www.wuxixdc.com

WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.

Executives

Shang Hai He Quan Yao Ye Gu Fen You Xian Gong Si
He Quan Yao Ye Xiang Gang Tou Zi You Xian Gong Si
Shang Hai Yao Ming Kang De Xin Yao Kai Fa You Xian Gong Si
Wu Xi Yao Ming Kang De Xin Yao Kai Fa Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Wuxi Biologics (cayman) Inc.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.

WuXi XDC Cayman Headlines

No Headlines